Microglial TREM2 in amyotrophic lateral sclerosis.

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with poorly understood mechanisms.
• Glial cells, particularly microglia (the CNS immune cells), are increasingly recognized for their role in ALS progression.
• Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is vital for microglial function and has been linked to neurodegenerative diseases.

Purpose of the Study:

• To review the function of microglial TREM2 in the context of ALS pathogenesis.
• To explore how microglial activation, specifically via TREM2, influences ALS progression.
• To identify TREM2 as a potential therapeutic target for ALS.

Main Methods:

• Literature review focusing on studies investigating microglial activation and TREM2 in ALS.
• Analysis of clinical and experimental data linking TREM2 function to ALS progression.
• Synthesis of current understanding of TREM2's role in microglial biology relevant to ALS.

Main Results:

• TREM2 is exclusively expressed on microglia in the CNS and regulates key microglial functions like proliferation, migration, and phagocytosis.
• Genetic links exist between TREM2 and neurodegenerative diseases, including ALS, although its precise role in ALS is still under investigation.
• Microglial activation, modulated by TREM2, significantly impacts ALS progression both clinically and experimentally.

Conclusions:

• Understanding the specific functions of TREM2 in microglia is crucial for elucidating ALS pathogenesis.
• Targeting microglial TREM2 pathways may offer a novel therapeutic strategy for treating ALS.
• Further research into TREM2's role can pinpoint molecular targets for effective ALS interventions.